We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s 2013 Appropriations Flat, Leaving Questions on Biosimilars
FDA’s 2013 Appropriations Flat, Leaving Questions on Biosimilars
May 8, 2012
Senate appropriators overwhelmingly approved a fiscal 2013 spending bill that provides $2.5 billion for the FDA but leaves no new money for biosimilars reviews needed for the agency to collect user fees.